Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Prostate and Urologic Cancer Research Group

Programs and Projects

Prostate Cancer Clinical Trials - H. Lee Moffitt Cancer Center and Research Institute

Agent: Polyphenon E
Contact: Nagi Kumar, PhD
DCP Program Director: Howard Parnes, MD

The purpose of this study is to see if polyphenon E can reduce the prevalence of prostate cancer in men with a pre-cancerous condition known as High Grade Prostatic Intraepithelial Neoplasia (HGPIN). Those taking part in the study will receive either polyphenon E or placebo for 12 months. The study is being conducted at the H. Lee Moffitt Cancer Center. The study will be open to accrual in the fall of 2007.

[This is a phase 2 randomized double-blind placebo controlled trial of polyphenon E for the chemoprevention of prostate cancer in subjects with High Grade PIN. The primary endpoint is the prevalence of biopsy detected prostate cancer in the group receiving polyphenon E as compared to the group receiving placebo.]